Announcements Trials
Browse Landscape

Phase

Phase 2 11Phase 1/2 6Phase 1 3Phase 4 1Phase 3 1

Status

Completed 20Withdrawn 4Terminated 3Active not recruiting 2

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Breast 1

Conditions

Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Leukemia, Biphenotypic, Acute 1Breast Neoplasms 1

Interventions

Cyclophosphamide 98pembrolizumab 85Gemcitabine 81Carboplatin 62fludarabine 61Nivolumab 57Cisplatin 54Paclitaxel 51Radiotherapy 50Docetaxel 49Rituximab 46Dexamethasone 42Lenalidomide 41Ipilimumab 38Azacitidine 35Etoposide 34Cytarabine 33Temozolomide 32Bevacizumab 32Radiation 29venetoclax 28Bortezomib 27Magnetic Resonance Spectroscopy 26Irinotecan 26Pemetrexed 25atezolizumab 24Oxaliplatin 24Capecitabine 24fludarabine phosphate 22Filgrastim 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Terminated × ixazomib × Clear all
NCT04405167 2025-10-07

Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

University of Pennsylvania

Phase 1 Terminated
30 enrolled
Plasma cell

Multiple Myeloma

NCT01887587 2020-01-22

Vincristine, Doxorubicin, And Dexamethasone + Ixazomib in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma Or Mixed Phenotype Acute Leukemia

Medical College of Wisconsin

Phase 1 Terminated
5 enrolled 9 charts
LymphoidOther hematologic neoplasm

Recurrence, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02384746 2019-04-29

Millennium

Dartmouth-Hitchcock Medical Center

Phase 1 Terminated
9 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡